Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503905 | 0.85 | HSD11B1 (0.47) | HSD11B1ALDH1A1EPHX2CNR2CNR1 | |
| SCHEMBL6507949 | 0.79 | HSD11B1 (0.50) | HSD11B1ALDH1A1EPHX2CNR2CNR1 | |
| SCHEMBL5161039 | 0.79 | HSD11B1 (0.52) | HSD11B1ALDH1A1EPHX2CNR2CNR1 | |
| SCHEMBL5155006 | 0.78 | HSD11B1 (0.47) | HSD11B1ALDH1A1EPHX2CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL5157982 | 0.78 | HSD11B1 (0.51) | HSD11B1ALDH1A1EPHX2CNR2CNR1 | |
| SCHEMBL5157481 | 0.70 | HSD11B1 (0.43) | HSD11B1ALDH1A1EPHX2CNR2CNR1 | |
| SCHEMBL40197 | 0.65 | SMN1; SMN2 (0.47) | ALDH1A1HSD17B10LMNA | |
| SCHEMBL5157285 | 0.64 | HSD11B1 (0.55) | HSD11B1ALDH1A1EPHX2 | |
| SCHEMBL1034049 | 0.63 | HSD11B1 (0.46) | HSD11B1EPHX2EPHX1L3MBTL1 | |
| SCHEMBL8245064 | 0.63 | PDK1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | HSD11B1 2/4885ALDH1A1 114/4885EPHX2 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.